Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2009

View Archived Issues

Dual-action inhibitors of coagulation factor Xa and thrombin reported by Bayer

New non-nucleoside reverse transcriptase inhibitors in development at GSK

Novel ERK2 inhibitors with oncolytic properties disclosed by Schering-Plough

Bristol-Myers Squibb divulges novel coagulation factor XIa and/or plasma kallikrein inhibitors

New renin inhibitors jointly imparted by Mitsubishi Tanabe Pharma and Shanghai Pharmaceutical

Theravance submits NDA to FDA for telavancin for nosocomial pneumonia

EpiCept reports positive results from phase IIb EpiCept trial

CLK-1 inhibition may explain the effect of clioquinol in neurodegenerative diseases

Priming with rAd41 vector expressing HIV Env facilitates mucosal immunity in mice

GSK-3beta inhibition with CU-GTSM improves cognitive function in Alzheimer's disease model

Altus realigns product development priorities and focuses on ALTU-238

CytRx reports 2009 clinical and development milestones

Inspire initiates phase III Prolacria trial under FDA special protocol

DelSite presents a report on company activities

DOR BioPharma forms medical advisory board to advise on development of DOR-201

Schering-Plough completes patient enrollment in phase III SPRINT-2 study of boceprevir

Sequenom initiates exchange offer to acquire EXACT Sciences for USD 41 million

Astellas proposes to acquire CV Therapeutics for USD 16 per share in cash

MHRA grants approval to Cortex to initiate study of CX-1739 in sleep apnea

Orexo and NovaMed sign licensing and distribution agreement for Abstral in China

Addex announces successful completion of phase I program of ADX-48621

ARCA biopharma and Nuvelo merge to create late-stage cardiovascular company

Callisto redirects atiprimod development to treat rheumatoid arthritis

FORMA Therapeutics collaborates with Cubist to discover novel antibacterial drugs

Oncolytics initiates patient enrollment in Reolysin colorectal cancer trial